Skip to main content
Clinical Pharmacology and Therapeutics logoLink to Clinical Pharmacology and Therapeutics
. 2020 Dec 13;109(5):1362. doi: 10.1002/cpt.2116

CORRIGENDUM: Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

PMCID: PMC8173634  PMID: 33870492

Arshad, U., et al., Clin. Pharmacol. Ther. 108, 775–790 (2020); https://doi.org/10.1002/cpt.1909

In the published version of the above article, the authors noticed a correction related to the data presented for baricitinib. The entry for barcitinib within the spreadsheet used for the analysis was erroneous, and the authors are unaware of any antiviral data for this drug. The data relating to baricitinib throughout the manuscript should therefore be disregarded. The inclusion of this erroneous value does not impact the overall interpretations or conclusions from the paper.

The authors apologize for this error.


Articles from Clinical Pharmacology and Therapeutics are provided here courtesy of Wiley and American Society for Clinical Pharmacology and Therapeutics

RESOURCES